(Q33183049)

23 July 2017

1 reference

title

The role interferon-alpha in malignant melanoma remains to be defined (English)

1 reference

23 July 2017

Eggermont AM

1

1 reference

23 July 2017

publication date

1 November 2001

1 reference

European Journal of Cancer

23 July 2017

published in

1 reference

23 July 2017

volume

37

1 reference

23 July 2017

issue

17

1 reference

23 July 2017

page(s)

2147-2153

1 reference

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Results of adjuvant interferon study in WHO melanoma programme

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Molecular staging of malignant melanoma: correlation with clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900272-6

7 January 2021

10.1016/S0959-8049(01)00272-6

Identifiers

DOI

1 reference

23 July 2017

1 reference